• Monitoring the Effects of Epirubicin, Cyclophosphamide, and Docetaxel in Women with Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Sweden
  • Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Hungary Poland Romania
  • Study on Reducing Antibiotic Duration for Pneumonia in Children Using Amoxicillin

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Study on Fibrinogen Replacement to Prevent Brain Bleeding in Stroke Patients After Thrombolysis

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    Italy
  • Study on Severe Erythema Multiforme: Comparing Methylprednisolone Acetate and Lidocaine Hydrochloride Monohydrate with Placebo for Hospitalized Patients

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    France
  • Study on L-Glutamic Acid and Sodium Chloride to Prevent Acute Kidney Injury in High-Risk Heart Surgery Patients Without Diabetes

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    Sweden
  • Study of Propranolol and Vinorelbine for Children and Teenagers with Refractory or Relapsing Solid Tumors

    Not yet recruiting

    1 1 1 1
    France
  • Study of perioperative versus post-surgery FOLFIRINOX (irinotecan, oxaliplatin, fluorouracil, and folinic acid) treatment in patients with resectable pancreatic cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    The Netherlands Sweden
  • Study on Trametinib for Patients with Neurofibromatosis Type 1 and Symptomatic Plexiform Neurofibromas

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands
  • Study of Avacopan Safety and Effectiveness in Patients with ANCA-associated Vasculitis

    Not yet recruiting

    3 1 1
    Czechia Denmark France Greece Hungary Poland +1

powered by